Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-specific neoantigen (frameshift peptide) refers to unique protein fragments generated exclusively within tumors due to coding region insertions/deletions that shift the genetic reading frame. These highly immunogenic antigens serve as ideal targets for next-generation cancer immunotherapies because they are absent from normal tissues, reducing autoimmune risk while enabling precise immune targeting against malignant cells.
Presentation on MHC-I molecules, leading to T cell receptor recognition and T cell-mediated cytotoxicity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-Specific Neoantigen (Frameshift Peptide) (Frameshift Peptide Neoantigen).